Zobrazeno 1 - 10
of 292
pro vyhledávání: '"SHYAM KOTTILIL"'
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Immunotargets including checkpoint inhibitors and toll-like receptor 8 agonists have recently gained attention for the recovery of hepatitis B virus (HBV)-specific T cell exhaustion in chronic hepatitis B(CHB). Chemokine receptors
Externí odkaz:
https://doaj.org/article/9737ea0b17fb4ad5b1b30e9066e403b6
Publikováno v:
Microorganisms, Vol 12, Iss 3, p 599 (2024)
Chronic hepatitis B (CHB) is a global health challenge that can result in significant liver-related morbidity and mortality. Despite a prophylactic vaccine being available, patients already living with CHB often must engage in lifelong therapy with n
Externí odkaz:
https://doaj.org/article/6d186c3e667f470cb6bb23bcd961fbdd
Autor:
Alip Ghosh, Arshi Khanam, Krishanu Ray, Poonam Mathur, Ananya Subramanian, Bhawna Poonia, Shyam Kottilil
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
CD38, a nicotinamide adenine dinucleotide (NAD)+ glycohydrolase, is considered an activation marker of T lymphocytes in humans that is highly expressed during certain chronic viral infections. T cells constitute a heterogeneous population; however, t
Externí odkaz:
https://doaj.org/article/c8992bf72e484e3fb0fde61a02c1373e
Autor:
Angela Y. Chang, Peter Aaby, Michael S. Avidan, Christine S. Benn, Stefano M. Bertozzi, Lawrence Blatt, Konstantin Chumakov, Shabaana A. Khader, Shyam Kottilil, Madhav Nekkar, Mihai G. Netea, Annie Sparrow, Dean T. Jamison
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
IntroductionRecent reviews summarize evidence that some vaccines have heterologous or non-specific effects (NSE), potentially offering protection against multiple pathogens. Numerous economic evaluations examine vaccines' pathogen-specific effects, b
Externí odkaz:
https://doaj.org/article/49bcd4de5ddc4956bbe39956f53222a2
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Treatment of chronic hepatitis C virus infection with direct acting antiviral therapy results in viral elimination in over 90% of cases. The duration of treatment required to achieve cure differs between individuals and relapse ca
Externí odkaz:
https://doaj.org/article/9c5becf715c1497fb3478514202136d4
Autor:
Arshi Khanam, Shyam Kottilil
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 437 (2022)
The incidence of liver cancer is continuously rising where hepatocellular carcinoma (HCC) remains the most common form of liver cancer accounting for approximately 80–90% of the cases. HCC is strongly prejudiced by the tumor microenvironment and be
Externí odkaz:
https://doaj.org/article/07233b729d054e58b1fe7dbbe79b4ede
Autor:
Arshi Khanam, Shyam Kottilil
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Acute-on-chronic liver failure (ACLF) is a multifaceted condition with poor treatment options and high short-term mortality. ACLF can develop in patients with or without liver cirrhosis, where patients with decompensated cirrhosis display a higher ri
Externí odkaz:
https://doaj.org/article/38a2a598a17f4d6e86fb2c4f229f21e3
Autor:
Natarajan Ayithan, Lydia Tang, Susanna K. Tan, Diana Chen, Jeffrey J. Wallin, Simon P. Fletcher, Shyam Kottilil, Bhawna Poonia
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Identifying signaling pathways that induce B cell response can aid functional cure strategies for chronic hepatitis B infection (CHB). TLR8 activation with ssRNA was shown to enhance follicular helper T cell (TFH) function leading to improved B cell
Externí odkaz:
https://doaj.org/article/037efbc6b5b94098a9d3891f7bb47e9f
Autor:
Shikha Shrivastava, Manasa Bhatta, Haley Ward, Sara Romani, Rebecca Lee, Elana Rosenthal, Anu Osinusi, Anita Kohli, Henry Masur, Shyam Kottilil, Eleanor Wilson
Publikováno v:
Hepatology Communications, Vol 2, Iss 12, Pp 1451-1466 (2018)
Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have higher levels of immune activation, impaired antigen‐specific responses, and accelerated fibrogenesis compared to patients monoinfected with HCV. Whether d
Externí odkaz:
https://doaj.org/article/491b5017cc5f46cc8da7d538019902c9
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Chronic Hepatitis B (CHB) affects over 350 million people worldwide. Current treatment does result in reduced complications; however, a cure (development of antibodies to the S antigen) is not achieved, requiring life-long therapy. Humoral responses
Externí odkaz:
https://doaj.org/article/f08871df87004b18ab809ed0427385f2